-
Je něco špatně v tomto záznamu ?
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
SN. Christiansen, S. Horskjær Rasmussen, M. Pons, B. Michelsen, B. Glintborg, B. Gudbjornsson, G. Grondal, J. Vencovsky, AG. Loft, Z. Rotar, KP. Pirkmajer, MJ. Nissen, J. Baranová, GJ. Macfarlane, GT. Jones, F. Iannone, R. Caporali, K. Laas, S....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- axiální spondyloartritida * MeSH
- bolest MeSH
- humanizované monoklonální protilátky * MeSH
- lidé MeSH
- psoriatická artritida * farmakoterapie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVES: In patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) initiating secukinumab, we aimed to assess and compare the proportion of patients achieving 6-, 12- and 24-month patient-reported outcomes (PRO) remission and the 24-month retention rates. PATIENTS AND METHODS: Patients with axSpA or PsA from 16 European registries, who initiated secukinumab in routine care were included. PRO remission rates were defined as pain, fatigue, Patient Global Assessment (PGA) ≤2 (Numeric Rating Scale (NRS) 0-10) and Health Assessment Questionnaire (HAQ) ≤0.5, for both axSpA and PsA, and were calculated as crude values and adjusted for drug adherence (LUNDEX). Comparisons of axSpA and PsA remission rates were performed using logistic regression analyses (unadjusted and adjusted for multiple confounders). Kaplan-Meier plots with log-rank test and Cox regression analyses were conducted to assess and compare secukinumab retention rates. RESULTS: We included 3087 axSpA and 3246 PsA patients initiating secukinumab. Crude pain, fatigue, PGA and HAQ remission rates were higher in axSpA than in PsA patients, whereas LUNDEX-adjusted remission rates were similar. No differences were found between the patient groups after adjustment for confounders. The 24-month retention rates were similar in axSpA vs. PsA in fully adjusted analyses (HR [95 %CI] = 0.92 [0.84-1.02]). CONCLUSION: In this large European real-world study of axSpA and PsA patients treated with secukinumab, we demonstrate for the first time a comparable effectiveness in PRO remission and treatment retention rates between these two conditions when adjusted for confounders.
Aberdeen Centre for Arthritis and Musculoskeletal Health University of Aberdeen UK
Amsterdam Rheumatology immunology Center Reade and Amsterdam UMC Amsterdam the Netherlands
Center for treatment of Rheumatic and Musculoskeletal Diseases Diakonhjemmet Hospital Oslo Norway
Centre for Rheumatology Research Landspitali University Hospital Reykjavik Iceland
Clinical Epidemiology Division Department of Medicine Solna Karolinska Institutet Stockholm Sweden
DANBIO registry Rigshospitalet Glostrup Denmark
Department for Rheumatology Landspitali University Hospital Reykjavik Iceland
Department of Clinical Medicine Aarhus University Aarhus Denmark
Department of Clinical Medicine University of Copenhagen Copenhagen Denmark
Department of Medicine Faculty of Medicine University of Porto Porto Portugal
Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic
Department of Rheumatology Aarhus University Hospital Aarhus Denmark
Department of Rheumatology East Tallinn Central Hospital Tallinn Estonia
Department of Rheumatology Geneva University Hospital Geneva Switzerland
Department of Rheumatology Hospital General Universitario Gregorio Marañón Madrid Spain
Department of Rheumatology University Medical Centre Ljubljana Ljubljana Slovenia
Departments of Medicine and Rheumatology Helsinki University Hospital Helsinki Finland
Faculty of Medicine Complutense University of Madrid Spain
Faculty of Medicine University of Iceland Reykjavik Iceland
Faculty of Medicine University of Ljubljana Ljubljana Slovenia
Institute of Biostatistics and Analyses Ltd Brno Czech Republic
Institute of Rheumatology Prague Czech Republic
National Institute for Health Development Tallinn Estonia
Public Health Section Inland Norway University of Applied Sciences Elverum Norway
Research Unit Sørlandet Hospital Kristiansand Norway
Research Unit Spanish Society of Rheumatology Spain
Rheumatology Department Centro Hospitalar e Universitário de São João Porto Portugal
Rheumatology Radboud University Medical Center Nijmegen the Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006566
- 003
- CZ-PrNML
- 005
- 20240423155347.0
- 007
- ta
- 008
- 240412e20240126xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.semarthrit.2024.152388 $2 doi
- 035 __
- $a (PubMed)38301349
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Christiansen, Sara Nysom $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark
- 245 10
- $a Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice / $c SN. Christiansen, S. Horskjær Rasmussen, M. Pons, B. Michelsen, B. Glintborg, B. Gudbjornsson, G. Grondal, J. Vencovsky, AG. Loft, Z. Rotar, KP. Pirkmajer, MJ. Nissen, J. Baranová, GJ. Macfarlane, GT. Jones, F. Iannone, R. Caporali, K. Laas, S. Vorobjov, DD. Giuseppe, T. Olofsson, SA. Provan, KM. Fagerli, I. Castrejon, L. Otero-Varela, M. van de Sande, I. van der Horst-Bruinsma, D. Nordström, L. Kuusalo, M. Bernardes, ML. Hetland, M. Østergaard, L. Midtbøll Ørnbjerg
- 520 9_
- $a OBJECTIVES: In patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) initiating secukinumab, we aimed to assess and compare the proportion of patients achieving 6-, 12- and 24-month patient-reported outcomes (PRO) remission and the 24-month retention rates. PATIENTS AND METHODS: Patients with axSpA or PsA from 16 European registries, who initiated secukinumab in routine care were included. PRO remission rates were defined as pain, fatigue, Patient Global Assessment (PGA) ≤2 (Numeric Rating Scale (NRS) 0-10) and Health Assessment Questionnaire (HAQ) ≤0.5, for both axSpA and PsA, and were calculated as crude values and adjusted for drug adherence (LUNDEX). Comparisons of axSpA and PsA remission rates were performed using logistic regression analyses (unadjusted and adjusted for multiple confounders). Kaplan-Meier plots with log-rank test and Cox regression analyses were conducted to assess and compare secukinumab retention rates. RESULTS: We included 3087 axSpA and 3246 PsA patients initiating secukinumab. Crude pain, fatigue, PGA and HAQ remission rates were higher in axSpA than in PsA patients, whereas LUNDEX-adjusted remission rates were similar. No differences were found between the patient groups after adjustment for confounders. The 24-month retention rates were similar in axSpA vs. PsA in fully adjusted analyses (HR [95 %CI] = 0.92 [0.84-1.02]). CONCLUSION: In this large European real-world study of axSpA and PsA patients treated with secukinumab, we demonstrate for the first time a comparable effectiveness in PRO remission and treatment retention rates between these two conditions when adjusted for confounders.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a psoriatická artritida $x farmakoterapie $7 D015535
- 650 _2
- $a výsledek terapie $7 D016896
- 650 12
- $a axiální spondyloartritida $7 D000089183
- 650 _2
- $a bolest $7 D010146
- 650 12
- $a humanizované monoklonální protilátky $7 D061067
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Horskjær Rasmussen, Simon $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark
- 700 1_
- $a Pons, Marion $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark. Electronic address: marion.claire.aliette.senlis@regionh.dk
- 700 1_
- $a Michelsen, Brigitte $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark; Research Unit, Sørlandet Hospital, Kristiansand, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway
- 700 1_
- $a Glintborg, Bente $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark; DANBIO registry, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 700 1_
- $a Gudbjornsson, Bjorn $u Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland
- 700 1_
- $a Grondal, Gerdur $u Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland
- 700 1_
- $a Vencovsky, Jiri $u Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Loft, Anne Gitte $u Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
- 700 1_
- $a Rotar, Ziga $u Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Pirkmajer, Katja Perdan $u Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Nissen, Michael J $u Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland
- 700 1_
- $a Baranová, Jana $u Institute of Biostatistics and Analyses, Ltd, Brno, Czech Republic
- 700 1_
- $a Macfarlane, Gary J $u Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, UK
- 700 1_
- $a Jones, Gareth T $u Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, UK
- 700 1_
- $a Iannone, Florenzo $u Rheumatology Unit, DiMePReJ, University of Bari, Italy
- 700 1_
- $a Caporali, Roberto $u Department of Rheumatology and medical sciences, ASST G. Pini-CTO, Milan and University of Milan, Milan, Italy
- 700 1_
- $a Laas, Karin $u Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia
- 700 1_
- $a Vorobjov, Sigrid $u National Institute for Health Development, Tallinn, Estonia
- 700 1_
- $a Giuseppe, Daniela Di $u Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Olofsson, Tor $u Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Rheumatology, Lund, Sweden
- 700 1_
- $a Provan, Sella Aarrestad $u Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Public Health Section, Inland Norway University of Applied Sciences, Elverum, Norway
- 700 1_
- $a Fagerli, Karen Minde $u Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway
- 700 1_
- $a Castrejon, Isabel $u Department of Rheumatology, Hospital General, Universitario Gregorio Marañón, Madrid, Spain; Faculty of Medicine, Complutense, University of Madrid, Spain
- 700 1_
- $a Otero-Varela, Lucia $u Research Unit, Spanish Society of Rheumatology, Spain
- 700 1_
- $a van de Sande, Marleen $u Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Institute for Infection & Immunity, Amsterdam, the Netherlands; Amsterdam Rheumatology immunology Center, Reade and Amsterdam UMC, Amsterdam, the Netherlands
- 700 1_
- $a van der Horst-Bruinsma, Irene $u Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands
- 700 1_
- $a Nordström, Dan $u Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland
- 700 1_
- $a Kuusalo, Laura $u Division of Internal Medicine, Centre for Rheumatology and Clinical Immunology, University of Turku and Turku University Hospital, Finland
- 700 1_
- $a Bernardes, Miguel $u Department of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal; Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
- 700 1_
- $a Hetland, Merete Lund $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 700 1_
- $a Østergaard, Mikkel $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 700 1_
- $a Midtbøll Ørnbjerg, Lykke $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark
- 773 0_
- $w MED00004315 $t Seminars in arthritis and rheumatism $x 1532-866X $g Roč. 65 (20240126), s. 152388
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38301349 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155344 $b ABA008
- 999 __
- $a ok $b bmc $g 2080892 $s 1216333
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 65 $c - $d 152388 $e 20240126 $i 1532-866X $m Seminars in arthritis and rheumatism $n Semin Arthritis Rheum $x MED00004315
- LZP __
- $a Pubmed-20240412
